Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer
The aim of the present study was to explore serum microRNA-155 (miR-155) expression in patients with colorectal cancer (CRC) and examined the potential usefulness of this molecule as a biomarker for diagnosis and prognosis in CRC. Serum samples were obtained between May 2007 and March 2013 from 146...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2015-03, Vol.36 (3), p.1619-1625 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1625 |
|---|---|
| container_issue | 3 |
| container_start_page | 1619 |
| container_title | Tumor biology |
| container_volume | 36 |
| creator | Lv, Zhong-chuan Fan, Yong-sheng Chen, Hong-bing Zhao, Da-wei |
| description | The aim of the present study was to explore serum microRNA-155 (miR-155) expression in patients with colorectal cancer (CRC) and examined the potential usefulness of this molecule as a biomarker for diagnosis and prognosis in CRC. Serum samples were obtained between May 2007 and March 2013 from 146 CRC patients and 60 healthy controls. Serum miR-155 expression levels were measured by quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR). Survival curves were obtained using the Kaplan–Meier method and assessed by the log-rank test. The receiver operating characteristic (ROC) curve was used for the prediction of cut-off values of the markers. Serum miR-155 expression level on average was upregulated in CRC patients compared with the matched healthy controls (
P
|
| doi_str_mv | 10.1007/s13277-014-2760-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1667345601</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1667345601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-3d1bcd2bd7b1c143872fa321f37a551b3aedfcc3cc194c9f25f46b8673127cca3</originalsourceid><addsrcrecordid>eNp1kVtr3DAQhUVoyGXbH9CXIuhLXtRodLHsxyXkBiGBkDwLeSwtTm1rI60L_ffRstkSAn2ShL45M3MOId-B_wLOzXkGKYxhHBQTpuKsOSAnoIRkXNb8S7lz4EyJWh6T05xfOAfdNNURORZai1qAOiHt7fTH502_cps-TjQGOvaY4uP9koHW1GXqaPZpHmnXu9UUC4rUTR1dp7h_tn0cXfrtEw0xUYxDTB43bqDoJvTpKzkMbsj-2_u5IM9Xl08XN-zu4fr2YnnHUPN6w2QHLXai7UwLCErWRgQnBQRpnNbQSue7gCgRoVHYBKGDqtq6MhKEQXRyQc52umW017ksZcc-ox8GN_k4ZwtVYZWuOBT05yf0Jc5pKtNtqRqKP1IVCnZUMSTn5INdp75s-tcCt9sA7C4AWwKw2wBsU2p-vCvP7ei7fxV7xwsgdkAuX9PKpw-t_6v6BhUTkF4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1668125534</pqid></control><display><type>article</type><title>Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Lv, Zhong-chuan ; Fan, Yong-sheng ; Chen, Hong-bing ; Zhao, Da-wei</creator><creatorcontrib>Lv, Zhong-chuan ; Fan, Yong-sheng ; Chen, Hong-bing ; Zhao, Da-wei</creatorcontrib><description>The aim of the present study was to explore serum microRNA-155 (miR-155) expression in patients with colorectal cancer (CRC) and examined the potential usefulness of this molecule as a biomarker for diagnosis and prognosis in CRC. Serum samples were obtained between May 2007 and March 2013 from 146 CRC patients and 60 healthy controls. Serum miR-155 expression levels were measured by quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR). Survival curves were obtained using the Kaplan–Meier method and assessed by the log-rank test. The receiver operating characteristic (ROC) curve was used for the prediction of cut-off values of the markers. Serum miR-155 expression level on average was upregulated in CRC patients compared with the matched healthy controls (
P
< 0.001). ROC curve analysis showed that miR-155 was a useful marker for discriminating cases from healthy controls, with an area under the ROC curve (AUC) of 0.776 (95 % confidence interval (CI) 0.714 to 0.837,
P
< 0.001). Kaplan–Meier analysis with the log-rank test indicated that high serum miR-155 expression had a significant impact on overall survival (38.2 vs. 69.9 %;
P
< 0.001) and progression-free survival (34.8 vs. 66.0 %;
P
< 0.001). In conclusion, the detection of miR-155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-014-2760-9</identifier><identifier>PMID: 25528214</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Colorectal cancer ; Colorectal Neoplasms - blood ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Disease-Free Survival ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Male ; Medical diagnosis ; Medical prognosis ; MicroRNAs ; MicroRNAs - blood ; MicroRNAs - genetics ; Middle Aged ; Neoplasm Staging ; Prognosis ; Research Article ; ROC Curve</subject><ispartof>Tumor biology, 2015-03, Vol.36 (3), p.1619-1625</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2014</rights><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-3d1bcd2bd7b1c143872fa321f37a551b3aedfcc3cc194c9f25f46b8673127cca3</citedby><cites>FETCH-LOGICAL-c508t-3d1bcd2bd7b1c143872fa321f37a551b3aedfcc3cc194c9f25f46b8673127cca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-014-2760-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-014-2760-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25528214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lv, Zhong-chuan</creatorcontrib><creatorcontrib>Fan, Yong-sheng</creatorcontrib><creatorcontrib>Chen, Hong-bing</creatorcontrib><creatorcontrib>Zhao, Da-wei</creatorcontrib><title>Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>The aim of the present study was to explore serum microRNA-155 (miR-155) expression in patients with colorectal cancer (CRC) and examined the potential usefulness of this molecule as a biomarker for diagnosis and prognosis in CRC. Serum samples were obtained between May 2007 and March 2013 from 146 CRC patients and 60 healthy controls. Serum miR-155 expression levels were measured by quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR). Survival curves were obtained using the Kaplan–Meier method and assessed by the log-rank test. The receiver operating characteristic (ROC) curve was used for the prediction of cut-off values of the markers. Serum miR-155 expression level on average was upregulated in CRC patients compared with the matched healthy controls (
P
< 0.001). ROC curve analysis showed that miR-155 was a useful marker for discriminating cases from healthy controls, with an area under the ROC curve (AUC) of 0.776 (95 % confidence interval (CI) 0.714 to 0.837,
P
< 0.001). Kaplan–Meier analysis with the log-rank test indicated that high serum miR-155 expression had a significant impact on overall survival (38.2 vs. 69.9 %;
P
< 0.001) and progression-free survival (34.8 vs. 66.0 %;
P
< 0.001). In conclusion, the detection of miR-155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - blood</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>MicroRNAs</subject><subject>MicroRNAs - blood</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Research Article</subject><subject>ROC Curve</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kVtr3DAQhUVoyGXbH9CXIuhLXtRodLHsxyXkBiGBkDwLeSwtTm1rI60L_ffRstkSAn2ShL45M3MOId-B_wLOzXkGKYxhHBQTpuKsOSAnoIRkXNb8S7lz4EyJWh6T05xfOAfdNNURORZai1qAOiHt7fTH502_cps-TjQGOvaY4uP9koHW1GXqaPZpHmnXu9UUC4rUTR1dp7h_tn0cXfrtEw0xUYxDTB43bqDoJvTpKzkMbsj-2_u5IM9Xl08XN-zu4fr2YnnHUPN6w2QHLXai7UwLCErWRgQnBQRpnNbQSue7gCgRoVHYBKGDqtq6MhKEQXRyQc52umW017ksZcc-ox8GN_k4ZwtVYZWuOBT05yf0Jc5pKtNtqRqKP1IVCnZUMSTn5INdp75s-tcCt9sA7C4AWwKw2wBsU2p-vCvP7ei7fxV7xwsgdkAuX9PKpw-t_6v6BhUTkF4</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Lv, Zhong-chuan</creator><creator>Fan, Yong-sheng</creator><creator>Chen, Hong-bing</creator><creator>Zhao, Da-wei</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer</title><author>Lv, Zhong-chuan ; Fan, Yong-sheng ; Chen, Hong-bing ; Zhao, Da-wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-3d1bcd2bd7b1c143872fa321f37a551b3aedfcc3cc194c9f25f46b8673127cca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - blood</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>MicroRNAs</topic><topic>MicroRNAs - blood</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Research Article</topic><topic>ROC Curve</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lv, Zhong-chuan</creatorcontrib><creatorcontrib>Fan, Yong-sheng</creatorcontrib><creatorcontrib>Chen, Hong-bing</creatorcontrib><creatorcontrib>Zhao, Da-wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lv, Zhong-chuan</au><au>Fan, Yong-sheng</au><au>Chen, Hong-bing</au><au>Zhao, Da-wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>36</volume><issue>3</issue><spage>1619</spage><epage>1625</epage><pages>1619-1625</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>The aim of the present study was to explore serum microRNA-155 (miR-155) expression in patients with colorectal cancer (CRC) and examined the potential usefulness of this molecule as a biomarker for diagnosis and prognosis in CRC. Serum samples were obtained between May 2007 and March 2013 from 146 CRC patients and 60 healthy controls. Serum miR-155 expression levels were measured by quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR). Survival curves were obtained using the Kaplan–Meier method and assessed by the log-rank test. The receiver operating characteristic (ROC) curve was used for the prediction of cut-off values of the markers. Serum miR-155 expression level on average was upregulated in CRC patients compared with the matched healthy controls (
P
< 0.001). ROC curve analysis showed that miR-155 was a useful marker for discriminating cases from healthy controls, with an area under the ROC curve (AUC) of 0.776 (95 % confidence interval (CI) 0.714 to 0.837,
P
< 0.001). Kaplan–Meier analysis with the log-rank test indicated that high serum miR-155 expression had a significant impact on overall survival (38.2 vs. 69.9 %;
P
< 0.001) and progression-free survival (34.8 vs. 66.0 %;
P
< 0.001). In conclusion, the detection of miR-155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25528214</pmid><doi>10.1007/s13277-014-2760-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2015-03, Vol.36 (3), p.1619-1625 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1667345601 |
| source | MEDLINE; Springer Online Journals |
| subjects | Adult Aged Aged, 80 and over Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Cancer Research Colorectal cancer Colorectal Neoplasms - blood Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Disease-Free Survival Female Gene expression Gene Expression Regulation, Neoplastic Humans Kaplan-Meier Estimate Lymphatic Metastasis Male Medical diagnosis Medical prognosis MicroRNAs MicroRNAs - blood MicroRNAs - genetics Middle Aged Neoplasm Staging Prognosis Research Article ROC Curve |
| title | Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A25%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20microRNA-155%20as%20a%20serum%20diagnostic%20and%20prognostic%20biomarker%20for%20colorectal%20cancer&rft.jtitle=Tumor%20biology&rft.au=Lv,%20Zhong-chuan&rft.date=2015-03-01&rft.volume=36&rft.issue=3&rft.spage=1619&rft.epage=1625&rft.pages=1619-1625&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-014-2760-9&rft_dat=%3Cproquest_cross%3E1667345601%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1668125534&rft_id=info:pmid/25528214&rfr_iscdi=true |